Physician profile
Archna Vajpayee
NPI 1821021148
$1,840.61
in general payments reported to CMS, 2019-2025
31 companies · $513 in 2025
The $513 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2021: $13.48 · 2022: $364 · 2023: $306 · 2024: $520 · 2025: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,339.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $232.77 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $224.96 | 2019-2025 | Evenity, Repatha, Prolia |
| Abbott Laboratories | $180.25 | 2022-2025 | Freestyle Libre 3 |
| Inspire Medical Systems, INC. | $165.94 | 2023-2025 | Inspire |
| Lilly USA, LLC | $135.72 | 2022-2025 | Mounjaro, Zepbound, Humulin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.51 | 2019-2025 | Jardiance |
| Tandem Diabetes Care, INC. | $69.37 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $62.33 | 2022-2025 | |
| Pfizer INC. | $53.61 | 2022-2024 | |
| Ibsa Pharma INC. | $51.80 | 2024-2025 | Licart, Tirosint, Flector |
| Exact Sciences Corporation | $49.77 | 2024-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $45.36 | 2024-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $42.41 | 2019 | |
| Astellas Pharma US INC | $41.64 | 2022-2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $40.83 | 2019-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $31.14 | 2025 | |
| Verity Pharmaceuticals INC. | $27.13 | 2024 | Tlando |
| Takeda Pharmaceuticals U.S.A., INC. | $25.78 | 2022 | |
| Tolmar, INC. | $22.30 | 2025 | Jatenzo |
| Sanofi Pasteur INC. | $21.91 | 2025 | |
| Zealand Pharma US, INC. | $20.83 | 2022 | |
| Glaxosmithkline, LLC. | $19.87 | 2023 | Shingrix |
| Boston Scientific Corporation | $19.85 | 2024 | Watchman Flx |
| Kyowa Kirin, INC. | $18.80 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $18.48 | 2022 | |
| Ironwood Pharmaceuticals, INC | $18.12 | 2019 | |
| Esperion Therapeutics, INC. | $17.43 | 2024 | Nexletol |
| Antares Pharma, INC. | $15.88 | 2024 | Xyosted |
| Kowa Pharmaceuticals America, INC. | $14.51 | 2022 | |
| Amneal Pharmaceuticals LLC | $12.73 | 2022 | |
| Dexcom, INC. | $12.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Archna Vajpayee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.